New Protein Target MOXD1 Opens Door to Treating Fatty Liver Disease
Scientists identify MOXD1 as a driver of MASH and show blocking it with a small molecule reverses liver fat accumulation in mice.
Summary
Metabolic dysfunction-associated steatohepatitis (MASH) — the advanced form of fatty liver disease — affects millions worldwide with few drug options. Researchers analyzed gene expression data from both mice and humans with MASH and pinpointed a previously overlooked protein called MOXD1 as a key culprit. MOXD1 works by interfering with a fatty acid-burning enzyme (ACOX1), steering it into a cellular compartment called the peroxisome in a way that blocks normal fat breakdown. Using AI-assisted drug screening, the team found a small molecule called rM15 that disrupts this interaction. In animal models of diet-induced MASH, rM15 significantly reduced liver fat buildup and disease progression. The findings nominate the MOXD1-ACOX1 pathway as a promising new drug target for a condition that currently has very limited treatment options.
Detailed Summary
Metabolic dysfunction-associated steatohepatitis (MASH) has become one of the most prevalent liver diseases globally, driven by the twin epidemics of obesity and type 2 diabetes. Despite its growing burden, pharmacological options remain scarce, making the identification of new molecular targets a clinical priority.
Researchers integrated multiple RNA-sequencing datasets from both mouse models and human MASH patients to identify genes consistently upregulated during disease. This analysis spotlighted MOXD1 — monooxygenase DBH like 1 — a gene not previously associated with liver fat metabolism. Hepatocyte-specific transgenic and knockout mouse models confirmed that MOXD1 expression worsens MASH phenotypes, while its deletion is protective.
Mechanistically, MOXD1 was found to physically interact with the ACOX1-PEX5 translocation complex. This interaction drives the fatty acid oxidation enzyme ACOX1 into peroxisomes in a manner that paradoxically suppresses lipolysis and lipophagy — two critical pathways for clearing lipid excess from liver cells. The team mapped four specific MOXD1 residues responsible for ACOX1 binding, providing precise structural information for drug design.
Leveraging these structural details and an AI-based screening platform, the investigators identified a small molecule inhibitor, rM15, that binds MOXD1 directly and disrupts its interaction with ACOX1. In cell-based assays, rM15 reduced hepatocyte lipid accumulation. In diet-induced MASH mouse models, rM15 treatment robustly suppressed disease progression, validating the therapeutic hypothesis in vivo.
While the findings are compelling, several caveats apply. The study is preclinical, and translation to humans requires clinical investigation. Functional data are from rodent models, and long-term safety of MOXD1 inhibition is unknown. Nonetheless, this work establishes the MOXD1-ACOX1 axis as a novel and mechanistically grounded therapeutic target for MASH.
Key Findings
- MOXD1 is a newly identified driver of MASH, confirmed in both human and mouse gene expression datasets.
- MOXD1 promotes ACOX1 peroxisome trafficking, blocking fat breakdown via lipolysis and lipophagy in liver cells.
- Four key MOXD1 residues mediate ACOX1 binding, offering precise targets for drug development.
- AI-designed small molecule rM15 disrupts the MOXD1-ACOX1 interaction and reverses liver fat accumulation in mice.
- Hepatocyte-specific MOXD1 knockout protects against diet-induced MASH, validating it as a therapeutic target.
Methodology
The study used multi-dataset RNA-seq integration from human and murine MASH to identify MOXD1, followed by hepatocyte-specific transgenic and knockout mouse models and an AAV8-based post-onset knockdown approach. Protein interaction mapping used co-immunoprecipitation mass spectrometry and structural modelling. Small molecule candidates were screened using an AI-based drug discovery model and validated in vitro and in diet-induced MASH mouse models.
Study Limitations
All functional and therapeutic data are preclinical, derived from cell culture and rodent models; human clinical validation is absent. The long-term safety profile of MOXD1 inhibition has not been established. This summary is based on the abstract only, as the full text was not available for review.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.